BCG administration promotes the long-term protection afforded by a single-dose intranasal adenovirus-based SARS-CoV-2 vaccine
D. J. Perera, P. Domenech, G. G. Babuadze, M. Naghibosadat, F. Alvarez, C. Koger-Pease, L. Labrie, M. Stuible, Y. Durocher, C. A. Piccirillo, A. Lametti, P. O. Fiset, S. M. Elahi, G. P. Kobinger, R. Gilbert, , M. Ndao
BCG enhances anti-SARS-CoV-2 immunity and protection afforded by a novel adenovirus-vectored vaccine.
bioRxiv · Mar 21, 2023Immunology